DESCRIPTION
Source： E. coliderived
Accession： P05231
Description : Synthetic DNA
fragment encoding whole human interleukin-6 (Accession number UniProtKB P05231, IL6_HUMAN) with
6His-tag on C-terminus was used for protein expression
Predicted Molecular Mass 20.9 kDa
Presentation: 20mM Tris-HCI，PH8.0
SPECIFICATIONS
SDS- PAGE 20.9 kDa, reducing
conditions.
Activity reaction with monoclonal antibodies specific to human IL6
Purity ≥ 90%
Concentration 1.7 mg/mL
Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method.
PREPARATION AND STORAGE
Shipping : The product is shipped
with dry ice or equivalent. Upon receipt, store it
immediately at the
temperature recommended below.
Stability & Storage： 12 months from date of
receipt, -20 to -80 °C as supplied.
3 months, 2 to 8 °C under
sterile conditions
Application: Used as Calibrator in
immunoassay，can be used as immune or screening
antigens.
BACKGROUND
Interleukin-6
(IL-6) is a multifunctional α-helical cytokine that regulates cell growth and differentiation of various tissues, which is known particularly for its role in
the immune response and acute phase reactions. IL-6 protein is secreted by a
variety of cell types including T cells and macrophages as a phosphorylated and
variably glycosylated molecule. It exerts actions through its heterodimeric
receptor composed of IL-6R that lacks the tyrosine/kinase domain and binds IL-6
with low affinity, and ubiquitously expressed glycoprotein 130 (gp130) that
binds the IL-6. IL-6R complex with high affinity and thus transduces signals.
IL-6 is also involved in hematopoiesis, bone metabolism, and cancer progression,
and has been defined as an essential role in directing the transition from
innate to acquired immunity.
1.Heinrich PC. et al. (2003). Principles of
interleukin-6-type cytokine signalling and its regulation. Biochem J. 374:
1-20.
2.Rose-John S, et al. (2007) The IL-6/sIL-6R
complex as a novel target for therapeutic approaches. Expert Opin Ther Targets.
11(5): 613-24.
3.Dinh W, et al. (2009) Elevated plasma levels of
TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose
metabolism disorders. Cardiovasc Diabetol. 8:58.
更多精彩内容敬请关注
粤公网安备 44030502008923号